



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Linda H. MALKAS et al

Conf. No.: 5889

Appln. No.: 10/083,576

Group Art Unit: 1645

Filed: February 27, 2002

Examiner: Unknown

For: METHOD FOR PURIFYING CANCER-SPECIFIC
PROLIFERATING NUCLEAR ANTIGEN

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed after three months from the application's filing date for an application other than a Continued Prosecution Application (CPA) under §1.53(d), but before the mailing date of the first Office Action on the merits. Therefore, no Statement under 37 C.F.R. § 1.97(a) is required under 37 C.F.R. § 1.97(b).

In submission that any such statement submitted prior to the

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No. 10/083,576

against the claims of the present application. Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,

Gordon Kit
Registration No. 30,764

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: October 22, 2002

OCT 22 2002

PTO SB 08 A & B (modified)

Substitute for Form 1449 A & B PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10 083,576
Confirmation Number	5889
Filing Date	February 27, 2002
First Named Inventor	Linda H. MALKAS et al
Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	A-7962

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 6,093,543		07/25/2000	Coll et al

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Ogata et al, <i>J. of Immunol.</i> , 135(4):2623-2627 (1985)	
		Malkas, "A Cancer Specific Form of Proliferating Cell Nuclear Antigen (csPCNA) Is Present in Malignant Human Cells and Tissues", Abstract, Presented at the MD Anderson Tumor Marker Meeting, Houston, Texas (March 2001)	
		Macedo et al, "Investigations on the Mechanism of Action of Novel Acylhydrazones and Sulfonylhydrazones Derivatives", <i>Proceedings of the American Association for Cancer Research</i> , Abstract No. 431, Volume 42, page 80 (March 2001)	
		Abdel-Aziz et al, "Effects of Cytosine Arabinoside, Camptothecin, and Etoposide on <i>In Vitro</i> DNA Replication Mediated by the Human Cancer Cell DNA Synthesome", <i>Proceedings of the American Association for Cancer Research</i> , Abstract No. 541, Volume 42, page 100 (March 2001)	
		Tomic et al, "Detection of the Cancer Specific Form of PCNA by Elisa Assay", <i>Proceedings of the American Association for Cancer Research</i> , Abstract No. 2507, Volume 42, page 466 (March 2001)	
		Smith et al, "Visualization of Cervical and Breast Cancer-Derived DNA Replication Complexes by Transmission Electron Microscopy", <i>Proceedings of the American Association for Cancer Research</i> , Abstract No. 2795, Volume 42, page 519 (March 2001)	
		Lankford et al, "Proteomic Analysis of the Human Breast and Ovarian DNA Synthesome Associated Mismatch Repair Proteins", <i>Proceedings of the American Association for Cancer Research</i> , Abstract No. 4797, Volume 42, page 894 (March 2001)	
		Hoelz et al, "Isolation and Characterization of the Non-Malignant Form of PCNA from MCF7 Breast Cancer Cells", <i>Proceedings of the American Association for Cancer Research</i> , Abstract No. 4798, Volume 42, page 894 (March 2001)	
		Hicke et al, "The Human Cell DNA Synthesome: A Novel <i>In Vitro</i> Model System for Evaluating Anticancer Drug Action", Abstract No. 137, <i>Anticancer Research</i> , 21:1577-1622 (2001)	
		Malkas et al, "Specific Functional and Structural Alteration of the Cancer Cells' DNA Replication Apparatus: Potential New Targets for Drug Development", Abstract No. 152, <i>Anticancer Research</i> , 21:1577-1622 (2001)	
		Hoelz et al, "Differential Binding of p21 ^{WAF1} by an Altered Form of PCNA Present in Breast Cancer Cells", Abstract, San Antonio Breast Cancer Symposium (December 2001)	
		Bechtel et al, <i>Advances in Brief, Cancer Research</i> , 58:3264-3269 (1998)	

Examiner Signature

Date Considered

* If a document is not a reference considered, whether or not citation is in conformance with MPEP 2100, Draw the line through citation number and mark "not considered".

† If a document is a reference, communication to applicant.